MedTrace Logo

The Suppression of Toll Like Receptors by Insulin

NCT01151605 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-01-05

No results posted yet for this study

Summary

This study will help us understand the possible beneficial effects of insulin in inflammation. Inflamamtion is considered to be the cause of atherosclerosis and heart disease.

Conditions

Interventions

DRUG

insulin infusion

insulin to be infused at 3.5 units/hour along with Dextrose 12.5% at a rate to achieve blood glucose levels between 80-120mg/dl

DRUG

Dextrose infusion

Dextrose 12.5% will be infused at a rate to maintain blood glucose level 80-120mg/dl

DRUG

Saline Infusion

Saline will be infused at 100ml/hr

Sponsors & Collaborators

Principal Investigators

  • Paresh Dandona, MBBS · The Research foundation of SUNY at Buffalo

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2013-09-30
Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01151605 on ClinicalTrials.gov